S&P 500

5.930,85

1,09%

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

0RKT

Selvita (0RKT)

Selvita Sa

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:LSE:0RKT

1 2 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
23/10/2024	09:26	PR Newswire (US)	Ryvu Therapeutics presents clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium	LSE:0RKT	Selvita Sa
09/10/2024	07:53	PR Newswire (US)	Ryvu Therapeutics to present clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium	LSE:0RKT	Selvita Sa
23/09/2024	11:31	PR Newswire (US)	Ryvu Therapeutics to present ONCO Prime platform at the 6th Annual RAS-Targeted Drug Development Summit	LSE:0RKT	Selvita Sa
14/06/2024	12:40	PR Newswire (US)	Ryvu Therapeutics presents clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress	LSE:0RKT	Selvita Sa
06/03/2024	06:40	UK Regulatory	Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting	LSE:0RKT	Selvita Sa
14/02/2024	15:12	UK Regulatory	Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS	LSE:0RKT	Selvita Sa
02/11/2023	12:02	PR Newswire (US)	Ryvu Therapeutics to Present Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting	LSE:0RKT	Selvita Sa
28/09/2022	14:17	PR Newswire (US)	Ryvu Therapeutics Reports 2022 Half-Year Financial Results and Provides Corporate Update	LSE:0RKT	Selvita Sa
10/06/2022	06:54	PR Newswire (US)	Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association (EHA) Congress	LSE:0RKT	Selvita Sa
08/03/2022	18:50	PR Newswire (US)	Ryvu Therapeutics to Present Data from its Oncology Programs at AACR 2022 Annual Meeting	LSE:0RKT	Selvita Sa
11/06/2021	05:30	PR Newswire (US)	Ryvu Therapeutics Presents Positive Phase I Data for RVU120 at the Virtual 26th Annual Congress of the European Hematology As...	LSE:0RKT	Selvita Sa
28/05/2021	09:08	PR Newswire (US)	Ryvu Therapeutics got full approval to conduct Phase I/II study of RVU120 (SEL120) in patients with relapsed/refractory metas...	LSE:0RKT	Selvita Sa
04/01/2021	18:05	PR Newswire (US)	Selvita completes acquisition of Fidelta from Galapagos	LSE:0RKT	Selvita Sa
01/12/2020	09:10	PR Newswire (US)	Three Posters on SEL24/MEN1703 including Pharmacodynamic Data from the Dose Escalation Part of DIAMOND-01 Trial to be publish...	LSE:0RKT	Selvita Sa
10/09/2020	07:51	PR Newswire (US)	Selvita reports strong financial results for H1 2020 and a record backlog	LSE:0RKT	Selvita Sa
10/06/2020	13:58	PR Newswire (US)	Ryvu Therapeutics Reports First Quarter 2020 Financial Results	LSE:0RKT	Selvita Sa
02/06/2020	11:20	PR Newswire (US)	Ryvu Therapeutics Has Completed the Construction of the R&D Center for Innovative Drugs	LSE:0RKT	Selvita Sa
26/05/2020	03:24	PR Newswire (US)	Selvita Reports Financial Results for Q1 2020: Dynamic Increase in Backlog for 2020 and Strong Position on the Market	LSE:0RKT	Selvita Sa
14/05/2020	10:30	PR Newswire (US)	Ryvu Therapeutics Announces Availability of Abstracts Regarding Phase 1/2 Study of SEL120 and SEL24/MEN1703 Accepted for Pres...	LSE:0RKT	Selvita Sa
27/04/2020	04:33	PR Newswire (US)	Selvita and Ardigen Will Receive Funding for the Development of an AI-based High-content Screening Platform	LSE:0RKT	Selvita Sa
16/04/2020	03:12	PR Newswire (US)	Galapagos and Ryvu Announce Research Collaboration	LSE:0RKT	Selvita Sa
27/02/2020	08:00	PR Newswire (US)	Ryvu Therapeutics to Present Recent Data From Multiple Oncology Programs at AACR 2020 Annual Meeting	LSE:0RKT	Selvita Sa
07/11/2019	08:30	PR Newswire (US)	Selvita Q3 2019 Results: Accelerated Growth, 45 Percent Increase in Commercial Revenues and Strong Long-term Outlook	LSE:0RKT	Selvita Sa
06/11/2019	13:39	PR Newswire (US)	Ryvu Therapeutics Announces Presentations on CDK8 Inhibitor SEL120 at the 61st ASH Annual Meeting	LSE:0RKT	Selvita Sa
06/11/2019	10:00	PR Newswire (US)	Ryvu Therapeutics Reports Third Quarter 2019 Financial Results	LSE:0RKT	Selvita Sa
01/10/2019	11:00	PR Newswire (US)	Ryvu Therapeutics and Selvita Announce Registration of Corporate Split by the National Court Register of Poland	LSE:0RKT	Selvita Sa
06/09/2019	03:00	PR Newswire (US)	Selvita Announces First Patient Dosed in Phase 1b Study of CDK8 Inhibitor SEL120 in the Treatment of Acute Myeloid Leukemia o...	LSE:0RKT	Selvita Sa
05/09/2019	03:00	PR Newswire (US)	Selvita Reports Second Quarter and Half-year 2019 Financial Results	LSE:0RKT	Selvita Sa
03/09/2019	14:00	PR Newswire (US)	Polish Financial Supervision Authority Approves Selvita CRO Prospectus, Allowing Corporate Split Into Two Separately Listed C...	LSE:0RKT	Selvita Sa
03/09/2019	06:00	PR Newswire (US)	Selvita to Present at Upcoming Conferences in September	LSE:0RKT	Selvita Sa